- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05577234
Contribution of Animal-assisted Intervention in Oral Healthcare for Disabled Patients (YODA) (YODA)
March 9, 2026 updated by: Assistance Publique - Hôpitaux de Paris
Contribution of Animal-assisted Intervention in Oral Healthcare for Disabled Patients
The purpose of this study is to determine whether animal-assisted therapy during 2 care sessions then facilitates conventional ambulatory management without animal assistance in anxious uncooperative children with autism.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The particularity of some disabled patients, especially those with an autism spectrum disorder, is represented by anxiety, which can range from a slight tension to screaming or even extreme agitation.
This behavior can make therapeutic management difficult, both for the patient and the caregiver.
This is particularly true for oral health care, where the cooperation of the patient is essential.
Conventional behavioral approaches, with implementation of a multitude of adaptive strategies, has a fundamental role to play.
With disabled patients, these techniques are most often based on non-verbal or para-verbal communication rather than on linguistic procedures.
In this context, an Animal Assisted Intervention could be of major help.
The primary outcome is average child anxiety during the session assessed by the Venham scale modified by Veerkamp measured at the end of the third session of care (without animal-assisted therapy).
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France
- Hôpital Bretonneau - Service d'odontologie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Minors aged ≥ 6 to ≤ 17 years,
- Carriers of Autism Spectrum Disorder.
- Child with an average Venham scale score ≥ 3 at the end of the care of the inclusion session
- Who accept the presence of the dog
- Who declare having been in contact with a dog in the past
- Consent from the child's legal guardians for the child's participation in the study,
- Be affiliated to a social security scheme in their own name or be the legal guardian of a person with parental authority.
- A state of health requiring a simple, non-complex dental procedure (preventive, carious, traumatic or orthodontic care, excluding complex surgery in the operating theatre)
- A state of health requiring a dental treatment protocol consisting of at least 3 scheduled treatment sessions spaced at least 7 days and no more than 21 days apart.
Exclusion Criteria:
- Child with dog allergy
- Cynophobia
- Who claims never to have been exposed to a dog (allergy risk not assessed)
- Patient on AME
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Animal-assisted intervention
The dog accompanied by the zootherapist will participate in the care of the sessions.
During these sessions, the dog will be brought into the child's presence in the waiting room until the end of the dental consultation.
|
The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation.
Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
|
|
Other: Standard care
The treatment sessions will only involve the use of conventional behavioural strategies.
|
The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average anxiety
Time Frame: through study completion, an average of 3 months
|
Average anxiety of the child during the session assessed by the Venham scale modified by Veerkamp measured at the end of the third treatment session (without animal assisted intervention).
Score on a scale : Min = 0 Max = 5 : 0 = relaxed, 1 = uneasy, 2 = tense, 3 = unwilling, 4 = very troubled, 5 = totally out of touch
|
through study completion, an average of 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the success of the care session (complete achievement of the planned objective)
Time Frame: at the end of each follow-up visit, on average 3 months
|
Overall success of the session: dental care completed in its entirety
|
at the end of each follow-up visit, on average 3 months
|
|
Validate the use of MEOPA administration
Time Frame: at the end of each follow-up visit, on average 3 months
|
Use of MEOPA: administration of MEOPA during the session
|
at the end of each follow-up visit, on average 3 months
|
|
Assess the types of acts for which animal assisted intervention reduces the child's anxiety
Time Frame: at the end of each follow-up visit, on average 3 months
|
Types of procedures for which animal assisted intervention reduces anxiety: assessment of anxiety by the Venham scale modified by Verkamp measured at the end of each type of procedure : waiting room, entry into practice, X-rays, anaesthesia, placement of the dam, use of rotary instruments
|
at the end of each follow-up visit, on average 3 months
|
|
Assessing the safety of animal assisted intervention for oral care
Time Frame: at the end of each follow-up visit, on average 3 months
|
Occurrence of undesirable events associated with the animal assisted intervention, including infectious events of the zoonosis type (assessment by the practitioner at the beginning of each session and by the accompanying person who must report to the practitioner any manifestation that has appeared since the last session), episodes of agitation linked to the presence of the dog, bites.
|
at the end of each follow-up visit, on average 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Jean-Marc Tréluyer, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 24, 2023
Primary Completion (Actual)
March 25, 2024
Study Completion (Actual)
March 25, 2024
Study Registration Dates
First Submitted
September 5, 2022
First Submitted That Met QC Criteria
October 10, 2022
First Posted (Actual)
October 13, 2022
Study Record Updates
Last Update Posted (Actual)
March 11, 2026
Last Update Submitted That Met QC Criteria
March 9, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP220662
- 2022-A00871-42 (Other Identifier: ID-RCB Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.